Newsfeeds - Spark Newswire

9 minute read

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

Today, 12:07 PM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

AEL

3 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 12:07 PM

ATRA

6 minute read

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 12:07 PM

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.

AEL

3 minute read

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

By Lisa Levin

Today, 12:07 PM

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

BBQ

1 minute read

Baird Maintains Outperform on Mersana Therapeutics, Raises Price Target to $20

By Benzinga Newsdesk

Today, 12:07 PM

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Outperform and raises the price target from $18 to $20.

MRSN

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 12:07 PM

AYTU

1 minute read

Earnings

Earnings Preview For Mersana Therapeutics

By Benzinga Insights

Today, 12:07 PM

Mersana Therapeutics (NASDAQ:MRSN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Mersana Therapeutics will report an earnings per share (EPS) of $-0.52.

MRSN

5 minute read

89 Biggest Movers From Friday

By Lisa Levin

Today, 12:07 PM

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

ADN

1 minute read

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

By Ragothaman Srinivasan

Today, 12:07 PM

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers.

MRSN

2 minute read

Mersana Therapeutics Announces FDA Grant Of Orphan Drug Designation To XMT-2056 For The Treatment Of Gastric Cancer

By Benzinga Newsdesk

Today, 12:07 PM

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical

MRSN